|
Warm Autoimmune Hemolytic Anemia (wAIHA)
Warm autoimmune hemolytic anemia (wAIHA) is the most common type (60-70%) of autoimmune hemolytic anemia (AIHA). In most cases, wAIHA is due an immunoglobulin G (IgG) autoantibody that binds to red blood cells (RBC), leading to hemolysis.
Current recommendations for managing people with wAIHA are largely based on case series and retrospective studies involving off-label medications. Also, while there are currently no medications specifically approved to treat wAIHA, data are emerging on new... |
|
Putting the Freeze on Cold Agglutinin Disease
STATEMENT OF NEED
Cold agglutinin disease (CAD) is a rare subtype of autoimmune hemolytic anemia (AIHA) in which antibodies cause hemolysis at cold temperatures, generally between 37º to 39º Fahrenheit. Approximately 1 in a million people are affected by CAD annually, with onset usually occurring between the ages of 40 and 80 years. Individuals commonly experience fatigue, dizziness, palpitations, and shortness of breath caused by the anemia; jaundice caused by degradation of hemoglobin i... |
|
|
Warm Autoimmune Hemolytic Anemia (wAIHA)
Target Audience
This activity has been designed to meet the educational needs of physicians specializing in hematology and hematology-oncology. Other members of the care team may also participate.
Program Overview
Warm autoimmune hemolytic anemia (wAIHA) is the most common type (60-70%) of autoimmune hemolytic anemia (AIHA). In most cases, wAIHA is due an immunoglobulin G (IgG) autoantibody that binds to red blood cells (RBC), leading to hemolysis.
Current recommendations for managing ... |
|
|
How I Treat Paroxysmal Nocturnal Hemoglobinuria (PNH)
In this point-counterpoint digital activity, two expert faculty discuss and debate treatment selection for patients with PNH through case-based scenarios. Faculty review mechanisms of action, clinical trial data, and real-world evidence supporting divergent treatment strategies for the presented cases. How do the experts make their initial treatment selections? Why might they choose a C5 inhibitor or a C3 inhibitor? How do they assess response to treatment, and what do they do when treatment r... |
|